Search for dissertations about: "Intraperitoneal chemotherapy"
Showing result 1 - 5 of 17 swedish dissertations containing the words Intraperitoneal chemotherapy.
-
1. Intraperitoneal Chemotherapy of Ovarian Cancer
Abstract : Ovarian cancer is still the most common cause of death among gynecologic malignancies in spite of the fact that newer and more effective drugs and/or administration techniques have been developed in the last decade. However, substantial improvements in response rate andprogression-free survival have been reported in many studies. READ MORE
-
2. Intraperitoneal 5-Fluorouracil treatment of cancer - clinical and experimental studies
Abstract : Background:Pancreas cancer is a most aggressive malignancy. More than 80% of patients diagnosed with pancreas cancer, exhibit such advanced disease, that curative surgery is impossible. Systemic chemotherapy prolongs survival to 5-9 months. READ MORE
-
3. A Pharmacokinetic and Pharmacodynamic Rationale for Perioperative Cancer Chemotherapy in Patients with Peritoneal Carcinomatosis
Abstract : Peritoneal carcinomatosis (PC) is a common manifestation of both gastrointestinal and gynecologic malignancies. Until recently, this condition was considered beyond curative intent treatment. Since the 1980s, new treatment strategies combining cytoreductive surgery (CRS) with perioperative intraperitoneal and intravenous chemotherapy have emerged. READ MORE
-
4. Loco-regional Treatment of Peritoneal Carcinomatosis: Survival, Morbidity and Quality of Life
Abstract : Peritoneal carcinomatosis (PC) is traditionally regarded as a terminal stage of disease with a poor prognosis and systemic chemotherapy is regarded as palliative treatment. In order to improve survival and even to achieve cure for selected patients with PC, cytoreductive surgery and intraperitoneal che-motherapy have been advocated. READ MORE
-
5. Clinical and Experimental Studies in Peritoneal Metastases from Gastric Cancer
Abstract : Gastric cancer (GC) is one of leading causes of death in the world, and peritoneal metastases (PM) are a major site of recurrence. PM from GC implies a poor prognosis, with median overall survival (mOS) approximately 3 months and no survival at five years. READ MORE